Search / Trial NCT00002106

A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

Launched by GLAXO WELLCOME · Aug 30, 2001

Trial Information

Current as of November 03, 2024

Completed

Keywords

Ranitidine

ClinConnect Summary

Patients are randomized to receive either ranitidine or matching placebo bid for 16 weeks, with follow-up every 4 weeks through week 20.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • Asymptomatic HIV-1 infection.
  • CD4 count of 400-700 cells/mm3.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • Significant illness.
  • Acute illness at randomization.
  • Hemodialysis.
  • Prior Medication:
  • Excluded:
  • Antiretroviral use within 60 days prior to study entry.

About Glaxo Wellcome

Glaxo Wellcome, a leading global biopharmaceutical company, is dedicated to advancing healthcare through innovative research and development of new therapies. With a strong focus on addressing unmet medical needs, Glaxo Wellcome combines scientific excellence with a commitment to improving patient outcomes across various therapeutic areas, including respiratory, infectious diseases, and oncology. The company is recognized for its robust clinical trial portfolio, leveraging cutting-edge technology and collaborative partnerships to drive the development of transformative treatments. Glaxo Wellcome upholds the highest ethical standards in clinical research, ensuring patient safety and integrity throughout the trial process.

Locations

Houston, Texas, United States

Durham, North Carolina, United States

Coral Gables, Florida, United States

Sherman Oaks, California, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials